State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease

Harald Hampel, Leslie M. Shaw, Paul Aisen, Christopher Chen, Alberto Lleó, Takeshi Iwatsubo, Atsushi Iwata, Masahito Yamada, Takeshi Ikeuchi, Jianping Jia, Huali Wang, Charlotte E. Teunissen, Elaine R. Peskind, Kaj Blennow, Jeffrey L. Cummings, Andrea VergalloAlzheimer 2021 · DOI

TL;DR

This review synthesizes the current evidence on the safety and utility of lumbar puncture (LP) for cerebrospinal fluid (CSF) biomarker analysis in Alzheimer's disease (AD). It argues that LP is a safe and cost-effective procedure, crucial for early AD diagnosis and the effective use of emerging disease-modifying therapies, and provides recommendations for optimizing its implementation globally.

What Problem Does This Paper Address?

The advent of disease-modifying therapies (DMTs) for Alzheimer's disease (AD) necessitates a paradigm shift towards early detection and diagnosis. This requires robust biomarker-guided approaches, with cerebrospinal fluid (CSF) analysis being a key component. However, the use of lumbar puncture (LP), the procedure for obtaining CSF, is inconsistent across regions and medical specialties. This inconsistency stems from varying perceptions of its safety, utility, and the presence of adverse events. This paper aims to address this gap by providing a comprehensive review of the state-of-the-art evidence on LP safety, risk factors for adverse events, and offering recommendations for its optimized and widespread implementation in AD diagnostics.

Methods

This paper is a systematic review and synthesis of existing literature. The authors critically analyze evidence from observational studies, clinical trials, and meta-analyses concerning the safety profile of LP in older adults, particularly those with suspected neurodegenerative diseases like AD. They also review evidence-based clinical guidance and recommendations for the optimized use of LP. Furthermore, the paper discusses emerging techniques that could enhance the operability, time-effectiveness, and safety of the procedure. The literature search was conducted using PubMed, Google Scholar, and other relevant sources.

Datasets

Not explicitly detailed as a dataset in the traditional sense. The review draws upon data from numerous existing studies, including large-scale prospective multicenter feasibility studies (e.g., BIOMARKAPD), observational studies, and meta-analyses involving thousands of patients. These studies collectively form the basis for the evidence presented on LP safety and adverse event rates.

Key Insights and Ideas

  • LP is a safe and essential tool for AD diagnostics: Despite concerns, the evidence strongly supports LP as a safe procedure in older adults, with low rates of serious complications.
  • CSF biomarkers are cost-effective and informative: Compared to other modalities like PET scans, CSF analysis is more cost-effective, resource-efficient, and can simultaneously assess multiple AD biomarkers (AT[N] system).
  • Perception, not just procedure, limits LP use: Hesitancy in using LP is driven by physician and patient perceptions of invasiveness and potential adverse events, rather than inherent procedural danger.
  • Risk factors are identifiable and manageable: While AEs like headache and back pain can occur, they are generally mild and manageable. Key risk factors (e.g., younger age, fear of the procedure) can be identified and addressed.
  • Optimized techniques enhance safety: Using atraumatic, narrow-bore needles and avoiding multiple attempts are crucial for minimizing complications.
  • Global implementation requires standardization and education: Harmonizing pre-analytical and analytical protocols for CSF analysis, alongside patient and physician education, is vital for widespread adoption.

Key Results

  • Low complication rates: Studies involving thousands of patients show that serious complications requiring specialist treatment are rare (<1%).
  • Common AEs are mild: Headache occurs in approximately 10-20% of cases and is usually mild and resolves without treatment. Back pain is reported by about 17% of patients.
  • Risk factors for AEs: Younger age, female sex, and fear of the procedure are associated with increased risk of AEs. Conversely, older age and a diagnosis of MCI or dementia are associated with a lower risk.
  • Needle type matters: Atraumatic needles significantly reduce the risk of post-LP headache and back pain compared to cutting-bevel needles.
  • Patient education is effective: Informing patients about the safety and benefits of LP can significantly improve their willingness to undergo the procedure and reduce anxiety.

Limitations and Future Work

  • Regional variability: While evidence is strong, there are significant regional differences in clinical practice and perceptions of LP, requiring further investigation into generalizability, particularly in Asian populations.
  • Harmonization of CSF biomarkers: Variability in CSF biomarker measurements across different platforms and laboratories remains a hurdle for widespread clinical use, necessitating global standardization of pre-analytical and analytical protocols.
  • System readiness: Healthcare systems need to adapt to accommodate the increased demand for LP and CSF analysis, addressing issues like resource constraints, reimbursement, and proper training.
  • Emerging techniques: Further development and validation of techniques like ultrasound-guided LP and virtual simulation training are promising for improving safety and feasibility.
  • Cost-effectiveness: While CSF biomarker analysis is generally considered cost-effective, especially with the availability of DMTs, further economic evaluations in diverse healthcare settings are needed.

Summary updated

Abstract

Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. Appropriate incorporation of cerebrospinal fluid biomarker analysis in clinical practice is an essential step toward system readiness for accommodating the demand of AD diagnosis and proper use of DMTs-once they become available. However, the use of lumbar puncture (LP) in individuals with suspected neurodegenerative diseases such as AD is inconsistent, and the perception of its utility and safety differs considerably among medical specialties as well as among regions and countries. This review describes the state-of-the-art evidence concerning the safety profile of LP in older adults, discusses the risk factors for LP-associated adverse events, and provides recommendations and an outlook for optimized use and global implementation of LP in individuals with suspected AD.
BibTeX
@inproceedings{hampel2021stateoftheart,
  author = {Harald Hampel and Leslie M. Shaw and Paul Aisen and Christopher Chen and Alberto Lleó and Takeshi Iwatsubo and Atsushi Iwata and Masahito Yamada and Takeshi Ikeuchi and Jianping Jia and Huali Wang and Charlotte E. Teunissen and Elaine R. Peskind and Kaj Blennow and Jeffrey L. Cummings and Andrea Vergallo},
  title = {{State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease}},
  booktitle = {Alzheimer},
  year = {2021},
  doi = {10.1002/alz.12372},
}

Loading related content...

Figure